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less costly than UFH. These ﬁndings were robust with
respect to changes in the background risk of throm-
boembolism and risk of death from competing causes.
CONCLUSIONS: Thromboprophylaxis with enoxaparin
represents a cost-effective use of health-care resources and
dominates strategies involving the use of UFH in acutely-
ill medical inpatients.
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OBJECTIVE: Controlled trials have demonstrated the
positive impact of statins on health outcomes in hyper-
lipidemic patients. However, few studies analyzed the
cost-effectiveness of adherence to statins. 
METHODS: Data were retrospectively gathered from a
commercial, integrated pharmacy/medical claims data-
base. Patients over 18 years with at least two statin
claims, a 120-day beneﬁt history, and a 360-day contin-
uous enrollment were selected for inclusion. Age, gender,
and concomitant drug/disease information were collected.
Adherence to statins was calculated as (total days sup-
plied)/(last claim date—ﬁrst claim date + last days
supply)*100. Total medical and drug costs, (TMDC),
including drug, hospital, physician visit and lab informa-
tion, were used to calculate per-member-per-month
(PMPM) costs during the follow-up period. Number of
patients and days to institutionalization for a disease-
related event (DRE) was determined and the costs for
DRE were calculated. ANOVA, or a non-parametric
equivalent, was used to test results across adherence 
quintiles.
RESULTS: 2317 patients (62% male) were included in
this analysis. The mean sample age was 53 with patients
taking an average of 7.1 medications concomitantly.
72.8% of patients were less than 80% adherent and
nearly 1/3 were less than 39% adherent. The median
TMDC for the sample was $379 PMPM, with costs sig-
niﬁcantly decreasing as adherence decreased (P < 0.0001).
The median cost for DRE was $313 PMPM, and also
decreased as adherence decreased, except for the >100%
adherent patients whose costs were less than the median,
though not signiﬁcantly (P = 0.703). Adherence was not
signiﬁcant in affecting the days to DRE (P = 0.4559). 
CONCLUSION: Although statins reduce cardiovascular
events over multiple years, this study conﬁrms that cost
savings cannot be expected in the ﬁrst year. If drug costs
are included in the total costs, one cannot expect an
increase in adherence to decrease the total direct health
care costs in the ﬁrst year of treatment.
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OBJECTIVE: To demonstrate differences in hospital
length-of-stay (LOS), charges, and mortality in CHF
patients by hospital and patient characteristics using 
the 1997 Hospital Cost and Utilization Project (HCUP)
database. 
METHODS: Hospitalizations with ICD-9-CM codes for
CHF were extracted from a 10% random HCUP sample
to yield 19,746 hospitalizations representing 22 states.
Hospital variables included region (Northeast, Midwest,
South, West), location (urban/rural), teaching/non-
teaching status, ownership (government, for-proﬁt, not
for-proﬁt), and hospital size (small, medium, large).
Patient variables included age (< = 50 years, 51–65 years,
>65 years), race (white, African-American, others),
gender, income (<$25,000, $25,000–$30,000, $30,000–
$35,000, >$35,000), number of comorbidities, and payer
status (Medicare, Medicaid, private/HMO, self-pay).
One-way ANOVA and chi-square statistics were used to
test for signiﬁcant (p < = 0.05) differences.
RESULTS: On average, CHF patients incurred charges of
$11,866 per hospitalization. The mean LOS per hospi-
talization was 5.83 days and the in-hospital mortality was
4.6 percent. LOS and hospital charges increased with
disease severity when patients were classiﬁed into 3 sever-
ity levels based on the number of comorbidities. Self-pay
patients had the longest LOS (8.69 days) but the lowest
charges ($11,418), and privately-insured/HMO patients
had the shortest LOS (5.33 days) but the highest charges
($13,381). For-proﬁt hospitals reported the highest mean
charges, followed by private/not proﬁt and government
hospitals. Mortality did not vary by region, location,
ownership and teaching status. Elderly patients (>65) 
had signiﬁcantly higher charges as compared to younger
patients (<50) ($ 13,817 vs. $11,607) and had higher
mortality (5.4% vs. 1.6%). High-income patients
incurred signiﬁcantly higher charges as compared to 
low-income patients ($13,456 vs. $10,840). Whites had
higher mortality (5.1%) as compared with others (4.6%)
and African-Americans (2.8%). LOS and charges did not
vary by race or gender. 
CONCLUSION: Hospital LOS, charges and mortality in
CHF patients show marked differences when compared
by patient and hospital characteristics.
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